Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al

Inna Friesen¹, Francesca Saluzzo², Ramona Groenheit³, Alexandra Aubry⁴, Richard Anthony⁵, Stefan Niemann⁶, Vanessa Mathys⁷, Daniela Maria Cirillo⁸; TB European Reference Laboratory Network (ERLTB-Net-3)

Collaborators, Affiliations

Collaborators

TB European Reference Laboratory Network (ERLTB-Net-3):
Alexander Indra⁹, Vanessa Mathys¹⁰, Yuliana Atanasova¹¹, Mihaela Obrovac¹², Ljiljiana Žmak¹², Despo Pieridou¹³, Věra Dvořákov¹⁴, Troels Lillebæk¹⁵, Tiina Kummik¹⁶, Kadri Klaos¹⁶, Hanna Soini¹⁷, Marjo Haanperä-Heikkinen¹⁸, Silja Mentula¹⁸, Robert Jérôme¹⁹, Emmanuelle Cambau²⁰, Stefan Niemann²¹, Ioannidis Panayotis²², Dimitrios Papaventsis²³, Ágnes Bakos²⁴, Viktória Szél²⁴, Lilla Katalin Lőrinczi²⁴, Margaret Fitzgibbon²⁵, Breida Boyle²⁵, Daniela Maria Cirillo²⁶, Federico Giannoni²⁷, Ilva Pole²⁸, Inga Norvaiša²⁸, Laima Vasiliauskaite²⁹, Monique Perrin³⁰, Catriona Deguara³¹, Richard Anthony³², Anne Torunn Mengshoel³³, Ewa Augustynowicz-Kopeć³⁴, Rita Macedo³⁵, Roxana Mihaela Coriu³⁶, Igor Porvaznik³⁷, Špela Klemen³⁸, Laura Herrera-León³⁹, Ramona Groenheit⁴⁰, Jim Werngren⁴⁰

Affiliations

¹ National and WHO Supranational Reference Laboratory for Tuberculosis, Research Center Borstel, Borstel, Germany.
² Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.
³ National and WHO Supranational Reference Laboratory for Tuberculosis, Public Health Agency of Sweden, Solna, Sweden.
⁴ Sorbonne Université, Inserm, U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France; AP-HP, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Laboratoire de Bactériologie-Hygiène, Centre National de Référence des mycobactéries et de la résistance des mycobactéries aux antituberculeux, Paris, France.
⁵ Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
⁶ National and WHO Supranational Reference Laboratory for Tuberculosis, Research Center Borstel, Borstel, Germany; Molecular and Experimental Mycobacteriology, Priority Area Infections, Research Center Borstel, Borstel, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
⁷ Human Bacterial Diseases Service, NRC Mycobacterium, Sciensano, Brussels, Belgium.
⁸ Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: cirillo.daniela@hsr.it.
⁹ Austrian Agency for Health and Food Safety (Central Office), Austria.
¹⁰ Sciensano, Belgium.
¹¹ National Centre of Infectious and Parasitic Diseases, Bulgaria.
¹² Croatian Institute of Public Health, Croatia.
¹³ Nicosia General Hospital, Cyprus.
¹⁴ National Institute of Public Health, Czech Republic.
¹⁵ Statens Serum Institut, Denmark.
¹⁶ Tartu University Hospital, Estonia.
¹⁷ National Institute for Health and Welfare (Turku), Finland.
¹⁸ National Institute for Health and Welfare, Finland.
¹⁹ Centre National de Référence des Mycobactéries, France.
²⁰ Hôpital Bichat - Claude-Bernard, France.
²¹ Centre for Medicine and Biosciences, Germany.
²² National Reference Laboratory for Mycobacteria, Greece.
²³ Molecular mycobacteriology laboratory, Sotiria Chest Diseases Hospital, Athens, Greece.
²⁴ Koranyi National Institute for Pulmonology, Hungary.
²⁵ Mycobacteria Reference Laboratory, Ireland.
²⁶ San Raffaele Scientific Institute, Italy.
²⁷ Istituto Superiore di Sanità (ISS), Italy.
²⁸ Riga East University Hospital, Latvia.
²⁹ National Tuberculosis and Infectious Diseases University Hospital, Lithuania.
³⁰ National Health Laboratory, Luxembourg.
³¹ Pathology Laboratory, Malta.
³² National Institute for Public Health and the Environment, Netherlands.
³³ Norwegian Institute of Public Health, Norway.
³⁴ National Tuberculosis and Lung Disease Institute, Poland.
³⁵ National Institute of Health Dr. Ricardo Jorge, Portugal.
³⁶ Marius Nasta Institute of Pulmonology, Romania.
³⁷ National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery, Slovak Republic.
³⁸ University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia.
³⁹ National Centre of Microbiology, Spain.
⁴⁰ Public Health Agency Sweden, Sweden.

PMID: 38851424
DOI: 10.1016/j.cmi.2024.06.001

Free article

Comment

Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al

Inna Friesen et al. Clin Microbiol Infect. 2024 Sep.

Free article

. 2024 Sep;30(9):1204-1206.

doi: 10.1016/j.cmi.2024.06.001. Epub 2024 Jun 6.

Authors

Collaborators

TB European Reference Laboratory Network (ERLTB-Net-3):
Alexander Indra⁹, Vanessa Mathys¹⁰, Yuliana Atanasova¹¹, Mihaela Obrovac¹², Ljiljiana Žmak¹², Despo Pieridou¹³, Věra Dvořákov¹⁴, Troels Lillebæk¹⁵, Tiina Kummik¹⁶, Kadri Klaos¹⁶, Hanna Soini¹⁷, Marjo Haanperä-Heikkinen¹⁸, Silja Mentula¹⁸, Robert Jérôme¹⁹, Emmanuelle Cambau²⁰, Stefan Niemann²¹, Ioannidis Panayotis²², Dimitrios Papaventsis²³, Ágnes Bakos²⁴, Viktória Szél²⁴, Lilla Katalin Lőrinczi²⁴, Margaret Fitzgibbon²⁵, Breida Boyle²⁵, Daniela Maria Cirillo²⁶, Federico Giannoni²⁷, Ilva Pole²⁸, Inga Norvaiša²⁸, Laima Vasiliauskaite²⁹, Monique Perrin³⁰, Catriona Deguara³¹, Richard Anthony³², Anne Torunn Mengshoel³³, Ewa Augustynowicz-Kopeć³⁴, Rita Macedo³⁵, Roxana Mihaela Coriu³⁶, Igor Porvaznik³⁷, Špela Klemen³⁸, Laura Herrera-León³⁹, Ramona Groenheit⁴⁰, Jim Werngren⁴⁰

Affiliations

¹ National and WHO Supranational Reference Laboratory for Tuberculosis, Research Center Borstel, Borstel, Germany.
² Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.
³ National and WHO Supranational Reference Laboratory for Tuberculosis, Public Health Agency of Sweden, Solna, Sweden.
⁴ Sorbonne Université, Inserm, U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France; AP-HP, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Laboratoire de Bactériologie-Hygiène, Centre National de Référence des mycobactéries et de la résistance des mycobactéries aux antituberculeux, Paris, France.
⁵ Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
⁶ National and WHO Supranational Reference Laboratory for Tuberculosis, Research Center Borstel, Borstel, Germany; Molecular and Experimental Mycobacteriology, Priority Area Infections, Research Center Borstel, Borstel, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
⁷ Human Bacterial Diseases Service, NRC Mycobacterium, Sciensano, Brussels, Belgium.
⁸ Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: cirillo.daniela@hsr.it.
⁹ Austrian Agency for Health and Food Safety (Central Office), Austria.
¹⁰ Sciensano, Belgium.
¹¹ National Centre of Infectious and Parasitic Diseases, Bulgaria.
¹² Croatian Institute of Public Health, Croatia.
¹³ Nicosia General Hospital, Cyprus.
¹⁴ National Institute of Public Health, Czech Republic.
¹⁵ Statens Serum Institut, Denmark.
¹⁶ Tartu University Hospital, Estonia.
¹⁷ National Institute for Health and Welfare (Turku), Finland.
¹⁸ National Institute for Health and Welfare, Finland.
¹⁹ Centre National de Référence des Mycobactéries, France.
²⁰ Hôpital Bichat - Claude-Bernard, France.
²¹ Centre for Medicine and Biosciences, Germany.
²² National Reference Laboratory for Mycobacteria, Greece.
²³ Molecular mycobacteriology laboratory, Sotiria Chest Diseases Hospital, Athens, Greece.
²⁴ Koranyi National Institute for Pulmonology, Hungary.
²⁵ Mycobacteria Reference Laboratory, Ireland.
²⁶ San Raffaele Scientific Institute, Italy.
²⁷ Istituto Superiore di Sanità (ISS), Italy.
²⁸ Riga East University Hospital, Latvia.
²⁹ National Tuberculosis and Infectious Diseases University Hospital, Lithuania.
³⁰ National Health Laboratory, Luxembourg.
³¹ Pathology Laboratory, Malta.
³² National Institute for Public Health and the Environment, Netherlands.
³³ Norwegian Institute of Public Health, Norway.
³⁴ National Tuberculosis and Lung Disease Institute, Poland.
³⁵ National Institute of Health Dr. Ricardo Jorge, Portugal.
³⁶ Marius Nasta Institute of Pulmonology, Romania.
³⁷ National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery, Slovak Republic.
³⁸ University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia.
³⁹ National Centre of Microbiology, Spain.
⁴⁰ Public Health Agency Sweden, Sweden.

PMID: 38851424
DOI: 10.1016/j.cmi.2024.06.001

No abstract available

Keywords: BPaLM availability; Bedaquline testing; MDR-TB; MDR-TB testing in EU/EAA; Pretomanid testing.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al

Collaborators

Affiliations

Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al

Authors

Collaborators

Affiliations

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources